article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease. The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6

article thumbnail

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

I’m coming at it from the perspective of understanding the science behind it… When you talk about manipulating genes, that definitely tends to put some people off,” she said. “I Trinkman noted the hesitancy some patients have shown toward gene therapies, emphasizing the need for greater education about how these therapies work. Subscribe Now!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reinventing Transplant Care: From Inpatient Tradition to Outpatient Innovation

Pharmacy Times

I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.

article thumbnail

FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Patients may receive this therapy regardless of PD-L1 expression or tumour histology.

article thumbnail

EC approves Regeneron’s Libtayo along with chemotherapy for NSCLC

Pharmaceutical Technology

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

article thumbnail

Kite releases pivotal CAR T therapy Phase III study results

European Pharmaceutical Review

Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy. According to Kite, these findings will be presented in full later this year at an upcoming scientific meeting.

article thumbnail

AstraZeneca to acquire Fusion for approximately $2bn

Pharmafile

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn.